Targeting the TGR5-GLP-1 pathway to combat type 2 diabetes and non-alcoholic fatty liver disease

Incretin-based therapies have shown promise in the treatment of type 2 diabetes. Here we review our current understanding of TGR5 as a target to induce glucagon-like peptide-1 (GLP-1) secretion. These new observations suggest that TGR5 agonists may constitute a novel approach to treat type 2 diabetes, as well as complications of diabetes, such as non-alcoholic fatty liver disease.


Published in:
Gastroenterol Clin Biol, 34, 4-5, 270-3
Year:
2010
Publisher:
Elsevier Masson
ISSN:
0399-8320
Keywords:
Laboratories:




 Record created 2010-07-09, last modified 2018-03-18


Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)